Harpoon Therapeutics Inc (HARP) concluded trading on Thursady at a closing price of $22.96, with 5.65 million shares of worth about $129.74 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 184.90% during that period and on Thursady the price saw a gain of about 1.50%. Currently the company’s common shares owned by public are about 16.95M shares, out of which, 9.90M shares are available for trading.
However, the stock later moved at a day high price of 22.96, or with a gain of 1.50%. Stock saw a price change of 2.27% in past 5 days and over the past one month there was a price change of 2.50%. Year-to-date (YTD), HARP shares are showing a performance of 101.93% which increased to 175.80% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.11 but also hit the highest price of $22.88 during that period. The average intraday trading volume for Harpoon Therapeutics Inc shares is 874.60K. The stock is currently trading 2.48% above its 20-day simple moving average (SMA20), while that difference is up 28.16% for SMA50 and it goes to 131.55% higher than SMA200.
Harpoon Therapeutics Inc (NASDAQ: HARP) currently have 16.95M outstanding shares and institutions hold larger chunk of about 75.96% of that.
The stock has a current market capitalization of $389.17M and its 3Y-monthly beta is at 2.11. It has posted earnings per share of -$8.71 in the same period. It has Quick Ratio of 1.89 while making debt-to-equity ratio of 3.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HARP, volatility over the week remained 0.88% while standing at 0.73% over the month.
Analysts are in expectations that Harpoon Therapeutics Inc (HARP) stock would likely to be making an EPS of -$0.64 in the current quarter, while forecast for next quarter EPS is -$0.82 and it is -$3.66 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.14 which is -$0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$5.5 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 89.77% while it is estimated to decrease by -63.74% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on January 05, 2024 offering an Outperform rating for the stock and assigned a target price of $23 to it. On July 06, 2022, Canaccord Genuity Resumed their recommendations, while on September 28, 2021, Citigroup Upgrade their ratings for the stock with a price target of $16. Stock get a Neutral rating from Citigroup on June 08, 2021.
